This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Mucopolysaccharidosis type I (Hurler / Hurler-Scheie / Scheie syndrome)Mucopolysaccharidosis Type I (MPS I / Hurler / Hurler-Scheie / Scheie Syndrome)

ItemDetails
A. Classification codesICD-10: E76.0 | Special Copayment Reduction: V117 | Coverage period: 5 years
B. SynonymsMucopolysaccharidosis type I, Hurler syndrome, Hurler-Scheie syndrome, Scheie syndrome — all correspond to E76.0 and form a phenotypic spectrum caused by the same IDUA gene defect
C. Adult onsetLikelihood of first onset in adulthood: very low — In the Hurler form, symptoms begin between 6 months and 2 years of age, with death before age 10 without treatment; the Scheie form has childhood onset, but diagnosis may be delayed until adulthood
SectionSummary
1. HistoryFirst described by Gertrud Hurler in 1917, with Scheie reporting the mild form in 1962. Cloning of the IDUA gene in 1992 opened the era of molecular diagnosis.
2. CausesAlpha-L-iduronidase enzyme deficiency due to IDUA gene mutations. Intralysosomal accumulation of heparan sulfate and dermatan sulfate causes multiorgan damage.
3. GeneticsIDUA gene located at 4p16.3 on chromosome 4. Autosomal recessive inheritance. Over 200 pathogenic variants reported. W402X and Q70X associated with the severe phenotype.
4. General epidemiologyAbout 0.23–0.34 per 100,000 births. The Hurler form accounts for over 60% of all MPS I. No sex difference.
5. PathophysiologyAlpha-L-iduronidase deficiency → incomplete GAG degradation → intralysosomal accumulation of HS and DS → cellular dysfunction → progressive multiorgan damage.
6. SymptomsCoarse facies, recurrent respiratory infections, cognitive regression, abdominal distension, hearing loss, joint contractures, corneal clouding. Severity varies by phenotype.
7. SignsHepatosplenomegaly, umbilical and inguinal hernias, thoracolumbar kyphosis, cardiac valve abnormalities, hydrocephalus. Confirmed by imaging, echocardiography, and audiometry.
8. ScreeningNeonatal dried blood spot (DBS) enzyme activity measurement, qualitative and quantitative urinary GAG testing. Molecular genetic testing needed for confirmation.
9. DiagnosisMeasurement of alpha-L-iduronidase enzyme activity in leukocytes or fibroblasts is the gold standard. IDUA gene analysis for confirmation and phenotype prediction.
10. TreatmentHurler form: early HSCT (hematopoietic stem cell transplantation) is standard; mild forms: weekly intravenous ERT with laronidase (Aldurazyme). Combined with multidisciplinary symptomatic treatment.
11. PrognosisMedian survival of untreated Hurler form 6.8 years. 5-year survival about 74% after successful early HSCT. Mild forms can survive into adulthood.
12. PreventionCarrier testing and prenatal diagnosis (amniocentesis, chorionic villus sampling), genetic counseling, PGT-M. Newborn screening allows early initiation of treatment.
13. References10 recent references (with PMID/DOI)

1. History

The history of mucopolysaccharidosis type I (MPS I) begins in 1917, when the Austrian pediatrician Gertrud Hurler first published in a journal cases of two boys with coarse facies, hepatosplenomegaly, skeletal abnormalities, and intellectual disability. Hurler described these cases under the nickname "gargoylism", a term used in clinical practice for decades. In 1941, the British Charles Hunter described two boys with a similar but X-linked form, which was later classified as MPS II (Hunter syndrome).

In 1962, the American ophthalmologist Harold Scheie separately described a mild form with corneal clouding and joint stiffness but preserved intelligence, naming it Scheie syndrome. The intermediate phenotype between Hurler syndrome and Scheie syndrome was called 'Hurler-Scheie syndrome'. Molecular biological research revealed that all three subtypes form a continuous phenotypic spectrum caused by the same IDUA gene defect, and they are now classified as severe (Hurler), intermediate (Hurler-Scheie), and mild (Scheie).

In 1971, Elizabeth Neufeld laid the theoretical foundation for the concept of enzyme replacement for lysosomal storage diseases through cell cross-correction experiments. In 1976, Bach et al. identified the deficient enzyme as alpha-L-iduronidase, and in 1992 Scott et al. cloned the IDUA gene on the short arm of chromosome 4, opening the era of molecular diagnosis. In the history of treatment, bone marrow transplantation was first attempted in the early 1980s, and from the 1990s hematopoietic stem cell transplantation (HSCT) was established as the standard treatment for Hurler syndrome. In 2003, laronidase (Aldurazyme) was approved by the US FDA and the European EMA, opening the era of enzyme replacement therapy. New treatment strategies such as combined HSCT and ERT and gene therapy clinical trials are currently being actively studied.

2. Causes

The direct cause of MPS I is deficiency or markedly reduced activity of the enzyme alpha-L-iduronidase, which degrades glycosaminoglycans (GAGs) stepwise within lysosomes. This enzyme hydrolyzes the nonreducing terminal iduronic acid residues of heparan sulfate (HS) and dermatan sulfate (DS). When enzyme activity is severely reduced or lost, undegraded GAG chains progressively accumulate in lysosomes, causing intracellular dysfunction and cell death.

When various pathogenic variants such as nonsense variants (W402X, Q70X, etc.), missense variants, splicing variants, and small insertions/deletions occur in the causative gene IDUA, structural abnormalities of the alpha-L-iduronidase protein, impaired post-translational modification, and defective lysosomal targeting result, leading to reduction or complete loss of enzyme activity. With almost no residual enzyme activity, the severe Hurler form appears; when some residual activity is maintained, a mild to intermediate phenotype appears.

GAG accumulation begins primarily within lysosomes but spreads secondarily to the extracellular matrix and to increased circulating GAG in the blood, triggering complex pathological mechanisms in tissues throughout the body, such as inflammatory responses, apoptosis, and disruption of growth factor signaling pathways. HS binds strongly to major growth factors such as FGF, VEGF, and TGF-β, so accumulated HS broadly affects the normal function of these signaling molecules. In this way, MPS I goes beyond a simple storage disorder, inducing complex secondary cell signaling abnormalities that cause multiorgan damage.

3. Genetics

The IDUA gene is located at position 16.3 of the short arm of chromosome 4 (4p16.3) and consists of 14 exons. Its protein product, alpha-L-iduronidase, is a lysosomal hydrolase of 654 amino acids that undergoes N-linked glycosylation and is targeted to lysosomes via mannose-6-phosphate (M6P) receptors.

Over 200 pathogenic variants have been reported in HGMD (Human Gene Mutation Database) and MPS I registry studies. By variant type, missense variants are the most common, followed by nonsense variants, splicing variants, small insertions/deletions, and large deletions. W402X (p.Trp402Ter) and Q70X (p.Gln70Ter), frequent in patients of Northern European descent, create premature termination codons, completely abolishing enzyme function, and are strongly associated with the severe Hurler form. In contrast, certain missense variants such as p.A75T and p.R89Q preserve some residual enzyme activity and are often associated with a mild phenotype.

MPS I is inherited in an autosomal recessive manner, and patients carry pathogenic variants in both IDUA alleles. The parents are each asymptomatic carriers of one pathogenic variant. The carrier frequency is estimated at about 1/100–1/200. The genotype-phenotype correlation is not complete, so clinical severity may differ even among carriers of the same variant. When both alleles carry complete loss-of-function variants (nonsense or major splicing variants), the severe Hurler form almost always appears. Genotype information is essential for determining HSCT indications, identifying carriers within the family, and prenatal diagnosis.

4. General epidemiology

MPS I is a rare lysosomal storage disease worldwide, with a prevalence of about 0.23 (Japan) to 0.34 (United States, Brazil) per 100,000 births. There is some variation by region and ethnicity, such as about 1.05 per 100,000 in the United Kingdom, 0.53 in the Netherlands, and 1.86 in British Columbia, Canada. The Hurler form (severe) accounts for about 60% or more of all MPS I patients, and there is no difference in occurrence by sex.

In Korea, accurate national prevalence data are insufficient, but patient numbers are being determined through Special Copayment Reduction registration and the rare disease registry program. In certain ethnic groups, the frequency of particular variants is high due to a founder effect (e.g., W402X in those of Northern European descent; separate high-frequency variants reported in Taiwanese and Japanese patient groups). Prospective prevalence data are accumulating in Taiwan and some US states, which have introduced newborn screening for MPS I, and a Taiwanese newborn screening study reported about 0.34 per 100,000 births.

5. Pathophysiology

The core pathogenic mechanism of MPS I is progressive accumulation of glycosaminoglycans within lysosomes. Normally, alpha-L-iduronidase hydrolyzes nonreducing terminal iduronic acid residues in the stepwise degradation of HS and DS. When the enzyme is deficient, this degradation process stops, and partially degraded GAG chains (oligosaccharides) accumulate in lysosomes. Intralysosomal GAG accumulation causes osmotic changes, lysosomal membrane instability, and disruption of the lysosome-autophagosome pathway, followed by secondary inflammatory mechanisms such as cytokine and chemokine activation, increased oxidative stress, and induction of apoptosis.

In particular, HS binds strongly to major growth factors and signaling molecules such as FGF, VEGF, TGF-β, and Wnt, so accumulated HS disrupts these signaling pathways, broadly affecting tissue development and maintenance of homeostasis. In the central nervous system, lysosomal GAG accumulation in neurons and glial cells, mitochondrial dysfunction, and neuroinflammation act in combination to cause cognitive regression. A key limitation of current treatment is that intravenously administered ERT enzyme does not sufficiently cross the blood-brain barrier, making it difficult to improve neurological pathology.

In the skeletal system, GAG accumulation in cartilage leads to growth plate dysfunction, spinal deformity, and joint contractures, and in the cardiovascular system, GAG deposition in valvular interstitial cells causes valve thickening, regurgitation, and stenosis. In the upper airway, GAG deposition in soft tissues and the trachea and bronchi causes airway obstruction and sleep apnea. HSCT works by continuously supplying donor-derived enzyme to tissues throughout the body, suppressing GAG accumulation over the long term.

6. Symptoms

The clinical symptoms of MPS I form a broad spectrum depending on phenotypic severity. In the severe Hurler form, symptoms begin to become evident between 6 months and 2 years of age. Typical early symptoms are recurrent otitis media and upper respiratory infections, umbilical or inguinal hernia, and coarse facies. Developmental milestones in this period are normal or slightly delayed, but rapid regression follows. Around age 1–2, developmental regression becomes evident, and slowing of height growth and abdominal distension due to hepatosplenomegaly become prominent. After age 2–3, rapid regression of cognitive, language, and motor function, decline in cardiopulmonary function, airway obstruction, and sleep apnea progress, and without treatment death usually occurs from cardiopulmonary failure before age 10.

In the Hurler-Scheie form (intermediate), cognitive function is relatively preserved, but skeletal, cardiac, and respiratory symptoms gradually progress. In the Scheie form (mild), cognitive function is nearly normal, but joint contractures, corneal clouding, cardiac valve abnormalities, and carpal tunnel syndrome progress cumulatively into adulthood, causing functional decline. In the mild form, early symptoms are subtle, and diagnosis is not uncommonly delayed until the teens or adulthood.

The main symptoms are listed below:

7. Signs

Typical signs observed on physical examination are as follows. On the face, frontal bossing, a depressed nasal bridge, thick lips, macroglossia, and a short, broad neck are characteristic. In the mild form, facial abnormalities are subtle and easily overlooked by general practitioners. In the eyes, corneal clouding is seen on slit-lamp examination as diffuse haziness, and glaucoma may also develop.

On abdominal examination, hepatosplenomegaly is invariably found and abdominal distension is prominent. Umbilical or inguinal hernias are also commonly observed. In the musculoskeletal system, finger contractures (claw hand) are characteristic; chest radiographs show 'oar-shaped' deformity of the ribs, and spinal radiographs show thoracolumbar hook vertebrae. Pelvic radiographs may show acetabular dysplasia and coxa valga.

A murmur may be heard on cardiac auscultation, and echocardiography shows thickening and regurgitation of the mitral and aortic valves, left ventricular hypertrophy, and cardiomyopathy. On neurological examination, the severe form shows findings of developmental regression, and a positive Tinel sign and Phalen test at the wrist suggest carpal tunnel syndrome. Skull radiographs and brain MRI show a 'J-shaped sella', ventricular enlargement, and white matter abnormalities. Qualitative urinary GAG testing is positive, and on quantitation the creatinine-corrected GAG value is increased above age-specific reference values. Audiometry shows conductive or mixed hearing loss.

8. Screening

Newborn screening for MPS I plays a key role in securing the optimal treatment timing for the severe Hurler form through presymptomatic diagnosis. Taiwan and some US states (Illinois, Missouri, etc.) currently perform newborn screening for lysosomal storage diseases including MPS I. Dried blood spot (DBS)-based enzyme activity measurement is most widely used, quantifying alpha-L-iduronidase activity by a fluorogenic substrate method or tandem mass spectrometry (MS/MS). Samples with reduced activity proceed to confirmatory testing (repeat blood sampling, repeat leukocyte enzyme activity measurement, genetic analysis).

Urinary GAG testing is useful for first-line screening of clinically suspected patients. The qualitative Toluidine blue spot test or Berry spot test is simple and inexpensive but has a false-negative rate. Confirming increased HS and DS bands through quantitative urinary GAG measurement (creatinine-corrected) and electrophoresis is more sensitive. Because urinary GAG excretion changes with age, age-adjusted reference values must be applied. If clinical suspicion is high, leukocyte enzyme activity should be measured despite a false-negative urinary GAG result.

In newborns with a family history, early diagnosis can be established by molecular genetic testing (IDUA gene analysis) immediately after birth. In Korea, MPS I is currently not included in the national newborn screening items, but rare disease registration and a stepwise diagnostic process for clinically suspected patients are used. Prenatal screening is performed in families of existing patients through CVS or amniocentesis.

9. Diagnosis

MPS I is confirmed on two pillars: alpha-L-iduronidase enzyme activity measurement and IDUA gene analysis.

Clinical evaluation

Clinical features suggestive of MPS I, such as coarse facies, hepatosplenomegaly, developmental delay/regression, recurrent respiratory infections, skeletal abnormalities, corneal clouding, and a history of recurrent hernias, are comprehensively evaluated. When these symptoms appear in combination in infants and young children, MPS must be included in the differential diagnosis. In the mild form, symptoms are nonspecific and diagnostic delay is common, so caution is needed.

Biochemical tests

In step 1, a pattern of increased HS and DS is confirmed by urinary GAG quantification (creatinine-corrected) and electrophoresis. In step 2, alpha-L-iduronidase enzyme activity is measured in leukocytes or skin fibroblasts by a fluorogenic substrate method or LC-MS/MS. Less than 5% of normal controls strongly suggests MPS I. Enzyme activity measurement using DBS can also be used for diagnostic purposes. To reduce false positives, measuring other lysosomal enzyme activities in the same sample at the same time is recommended.

Molecular genetic testing

Pathogenic variants are identified by sequencing all exons and adjacent introns of the IDUA gene (Sanger or NGS panel). Genotype information is used for phenotype prediction (severe vs mild), determining HSCT indications, identifying family carriers, and prenatal diagnosis. Large deletions and rearrangements are confirmed by MLPA or aCGH. For differential diagnosis, other lysosomal storage diseases such as MPS II, MPS III, MPS IV, MPS VI, mucolipidosis II/III, and mannosidosis are considered, and differentiation is possible by the enzyme activity pattern and the type of urinary GAG electrophoresis bands.

10. Treatment

The treatment strategy for MPS I differs according to phenotypic severity, combining disease-modifying treatment with multidisciplinary symptomatic treatment.

Hematopoietic stem cell transplantation (HSCT)

This is the standard treatment for the severe Hurler form. International consensus recommends performing it before neurological damage progresses, before 24 months of age and, if possible, within 12–18 months. After transplantation, donor-derived cells engraft in tissues throughout the body and continuously supply the enzyme, suppressing GAG accumulation over the long term. HSCT is effective in improving hepatosplenomegaly, airway obstruction, cardiac function, hearing, and joint mobility, and especially with early transplantation it preserves cognitive development. Cord blood transplantation achieves full donor chimerism more easily than bone marrow transplantation.

Enzyme replacement therapy (ERT)

Laronidase (Aldurazyme; Sanofi Genzyme) is a recombinant human alpha-L-iduronidase approved by the FDA and EMA in 2003. 0.58 mg/kg is administered intravenously once a week over about 3–4 hours. In patients with mild to intermediate disease (Scheie and Hurler-Scheie forms), improvement in pulmonary function, improved walking ability, reduction in hepatosplenomegaly, and reduction in urinary GAG were demonstrated in randomized controlled trials. In the severe Hurler form, it is used as bridging therapy before HSCT, and in some cases combined use after HSCT is also considered. Owing to poor passage across the blood-brain barrier, it is limited in improving neurological pathology. Hypersensitivity reactions may occur, so premedication and appropriate monitoring are needed.

Multidisciplinary symptomatic treatment

As needed, airway management (positive airway pressure or airway surgery for sleep apnea), regular cardiac monitoring and valve surgery, tympanostomy tube insertion, intraocular pressure control and corneal transplantation, orthopedic surgery such as spinal fusion and decompression, carpal tunnel release, cerebrospinal fluid shunting, and rehabilitation support including physical, occupational, and speech therapy are provided.

Research on new treatments

Clinical trials of receptor-mediated delivery enzymes for crossing the blood-brain barrier, substrate reduction therapy, pharmacological chaperones, and lentivirus- and AAV-based gene therapy are under way. Intrathecal or intravenous gene therapy is raising hopes for overcoming neurological pathology.

11. Prognosis

The prognosis of MPS I varies greatly depending on phenotype and whether treatment is given. The median survival of the untreated Hurler form (severe) is about 6.8 years, and most die from cardiopulmonary failure before age 10. In an analysis of 258 patients who underwent HSCT in 1995–2007, the 5-year survival after transplantation was about 74%, and with successful transplantation many survive into adulthood. In 30-year follow-up data from the University of Minnesota, all MPS I-H patients who survived more than 1 year after transplantation were alive at the time of follow-up, with a median age of 21 years. However, surviving patients also bear an ongoing long-term burden such as cardiac valve disease, orthopedic complications, hearing loss, and hydrocephalus, so multidisciplinary management is essential.

With ERT and appropriate symptomatic treatment, patients with the mild Scheie form can survive into adulthood while maintaining considerable function, but quality of life is affected by progressive joint contractures, cardiac valve abnormalities, decreased vision, and so on. Early diagnosis and early initiation of treatment are key factors improving prognosis in all subtypes. Presymptomatic HSCT through newborn screening is expected to further improve neurological outcomes in the future. If clinical application of gene therapy becomes a reality, the prognosis of severe MPS I may also improve dramatically.

12. Prevention

Because MPS I is a hereditary disease, primary prevention is achieved through genetic counseling, carrier testing, and prenatal and preimplantation genetic diagnosis. Secondary prevention aims to minimize disease progression through early detection by newborn screening and initiation of treatment at the optimal time.

In genetic counseling, the autosomal recessive mode of inheritance and recurrence risk (25%) are explained to families of children with MPS I, and carrier status is confirmed through IDUA gene analysis of both parents. Because enzyme activity alone is insufficient to identify carriers, molecular genetic testing is essential. Prenatal diagnosis is made by fetal enzyme activity measurement and IDUA gene analysis through chorionic villus sampling (CVS) at 10–12 weeks of gestation or amniocentesis at 15–18 weeks of gestation. Preimplantation genetic testing (PGT-M) is a method of selecting and transferring embryos that do not carry the pathogenic variants in carrier couples who choose in vitro fertilization (IVF), allowing prevention without termination of pregnancy. The expanded introduction of newborn screening enables presymptomatic early diagnosis, contributing to HSCT at the optimal time and minimization of neurological damage.

13. References

  1. Clarke LA, Wraith JE, Beck M, et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics. 2009;123(1):229-240. PMID: 19117887
  2. Aldenhoven M, Jones SA, Bonney D, et al. Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines. Biol Blood Marrow Transplant. 2015;21(6):1106-1109. PMID: 25709186
  3. Muenzer J, Wraith JE, Clarke LA; International Consensus Panel. Mucopolysaccharidosis I: management and treatment guidelines. Pediatrics. 2009;123(1):19-29. PMID: 19117856
  4. Tolar J, Grewal SS, Bjoraker KJ, et al. Combination of enzyme replacement and hematopoietic stem cell transplantation as therapy for Hurler syndrome. Bone Marrow Transplant. 2008;41(6):531-535. PMID: 18084329
  5. Scott HS, Bunge S, Gal A, Clarke LA, Morris CP, Hopwood JJ. Molecular genetics of mucopolysaccharidosis type I: diagnostic, clinical, and biological implications. Hum Mutat. 1995;6(4):288-302. PMID: 8680402
  6. de Ru MH, Boelens JJ, Das AM, et al. Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with MPS type I: results of a European consensus procedure. Orphanet J Rare Dis. 2011;6:55. PMID: 21861889
  7. Aldenhoven M, Wynn RF, Orchard PJ, et al. Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study. Blood. 2015;125(13):2164-2172. PMID: 25628467
  8. Hampe CS, Voss R, Tong P, et al. Long term disease burden post-transplantation: three decades of observations in 25 Hurler patients successfully treated with HSCT. Orphanet J Rare Dis. 2021;16(1):48. PMID: 33499879
  9. Vijay S, Wraith JE. Clinical presentation and follow-up of patients with the attenuated phenotype of mucopolysaccharidosis type I. Acta Paediatr. 2005;94(7):872-877. PMID: 16188803
  10. Lachmann RH, Clarke LA. Mucopolysaccharidosis Type I. In: Adam MP, et al., eds. GeneReviews [Internet]. Seattle: University of Washington; 1993-2023. Available: https://www.ncbi.nlm.nih.gov/books/NBK1162/